Spero Therapeutics (SPRO) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Portfolio overview and strategic focus

• Focus on oral small molecule drugs for rare and multi-drug resistant infectious diseases, with strong IP and orphan drug/QIDP designations.

• Lead asset SPR720 targets NTM-PD, a rare disease with high unmet need and no approved first-line therapies.

• Tebipenem HBr is in phase III for complicated urinary tract infections, partnered with GSK for global rights ex-Asia.

• SPR206 targets multi-drug resistant Gram-negative pathogens, partnered with Everest Medicines and Pfizer, with U.S. rights retained.

• Cash runway extends into late 2025, supported by partnerships and milestone payments.

SPR720 clinical development and potential

• SPR720 is a novel oral gyrase B inhibitor for NTM-PD, with proof-of-concept data expected in Q4 2024.

• Demonstrated in vitro and in vivo potency, with no cross-resistance to current antibiotics and low resistance selection.

• Healthy volunteer studies showed good tolerability and dose-dependent plasma exposure.

• Ongoing clinical study with 25 patients, 56 days dosing, primary endpoint is reduction in lung bacterial burden.

• Secondary endpoints include time to positivity, safety, tolerability, and PK; positive data could lead to pivotal trials.

NTM-PD disease landscape and unmet need

• NTM-PD affects about 245,000 patients in developed markets, with 100,000 in the U.S.

• Current standard of care involves long-term, poorly tolerated antibiotic combinations, with high resistance and recurrence rates.

• Five-year all-cause mortality is 35%, highlighting the need for new therapies.

• No approved first-line or oral therapies are currently available or in development, except for inhaled amikacin in phase III.

• SPR720 could be the first approved oral therapy, improving outcomes and tolerability.